Serina Therapeutics, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
AL
Business Address
601 GENOME WAY, HUNTSVILLE, AL, 35806
Mailing Address
601 GENOME WAY, HUNTSVILLE, AL, 35806
Phone
(256) 327-9630
Fiscal Year End
1231
EIN
821436829
Financial Overview
FY2025
$6.99M
Total Liabilities
$-1.51
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K/A Annual report amendment | March 27, 2026 | View on SEC |
| 10-K Annual financial report | March 25, 2026 | View on SEC |
| 8-K Current report of material events | March 25, 2026 | View on SEC |
| 4 Insider stock transaction report | March 24, 2026 | View on SEC |
| 8-K Current report of material events | March 23, 2026 | View on SEC |
| 4 Insider stock transaction report | March 20, 2026 | View on SEC |
| 4 Insider stock transaction report | February 17, 2026 | View on SEC |
| 4 Insider stock transaction report | February 17, 2026 | View on SEC |
| 4 Insider stock transaction report | February 17, 2026 | View on SEC |
| 4 Insider stock transaction report | February 17, 2026 | View on SEC |
Annual Reports
10-K
March 25, 2026
- Proprietary POZ delivery system improves existing drug efficacy and reduces side effects.
- Lead candidate SER-252 for Parkinson’s disease entered human clinical trials in February 2026.
Material Events
8-K
Financial Distress
January 15, 2026
High Impact
- Opportunity to submit a detailed plan by February 8, 2026, to regain compliance with NYSE American listing standards.
- Potential for an 18-month 'Cure Period' until July 9, 2027, if the recovery plan is accepted, allowing continued trading.
8-K
Other
December 10, 2025
High Impact
- Serina Therapeutics submitted a complete response to the FDA regarding a clinical hold on its lead drug program, SER-252, for advanced Parkinson's disease.
- The clinical hold, issued by the FDA, had paused human trials due to serious questions or concerns, likely about safety or trial design.
Insider Trading
SELL
1 insiders
19 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
NERVGEN PHARMA CORP.
NGEN
Pharmaceutical Preparations
Connect Biopharma Holdings Ltd
CNTB
Pharmaceutical Preparations
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
LIXT
Pharmaceutical Preparations
TuHURA Biosciences, Inc./NV
HURA
Pharmaceutical Preparations
Canton Strategic Holdings, Inc.
CNTN
Pharmaceutical Preparations
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.